Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 801–895 of 895
Samuel, P. (2016) · Radar (Oxford Brookes University) · doi:10.24384/bhrw-wn75
Human epididymis protein 4 (HE4) in chemo-response and prognosis of epithelial ovarian cancer
이승호 (2015) · Seoul National University Open Repository (Seoul National University)
Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer
Ferraioli, D. (2019) · theses.fr (ABES) · doi:10.70675/70428e9fz3367z4bf2zaa20zbe01338d59ad
Anant, M., Samanta, S., & Sinha, R. (2020) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20200801
“Lowgrade tumours, including borderline ovarian tumours, are characterised by mutations of the BRAF/KRAS pathway.(11,12) Two different mutation pathways prove that”
BackgroundAlbalbeisi, N. (2019) · NECTAR - Northampton Electronic Collection of Thesis and Research (University of Northampton)
Vrabie, C. D., Gangal, M., & Gangal, M. (2020) · medRxiv · doi:10.1101/2020.08.05.20168849
Korelasi Ekspresi CD47 terhadap Faktor-Faktor Klinikopatologi pada Karsinoma Ovarium
Fitrianti, F., Maulani, H., & Aspitriani, A. (2020) · SRIWIJAYA JOURNAL OF MEDICINE · doi:10.32539/sjm.v3i1.64
Clinical value of KI-67 index in tumor tissue in patients with stage I and II ovarian cancer
Nikogosyan, S. O., Baryshnikov, A. Y., Степанова, Е. В., Кузнецов, В. В., & Карапетян, В. Л. (2014) · Russian Journal of Oncology · doi:10.17816/onco40112
Optical coherence tomography imaging of ovarian cancer invasion
Hallas-Potts, A. (2021) · ERA · doi:10.7488/era/1045
The Impact of Follicular Fluid on Oviductal Epithelial Cell Gene Expression
Lau, A. (2014) · TSpace (University of Toronto)
Zamani, N., Modares, M., & Zamani, F. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-esgo.125
Reportage: ‘Broeders’ van Jetse Batelaan op de Wiener Festwochen
van den Berg, S. (2008)
HE4: another 'player' in the epithelial tumor marker arena?
Teplinsky, E., & Muggia, F. M. (2013) · PubMed
The Role of Trop2 Cleavage Products in Prostate Tumorigenesis
Stoyanova, T. I. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada612359
Immunohistochemistry of Gynecologic Malignancies
Wang, Y., & Mhawech-Fauceglia, P. Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-17002-2_65-1
Dietel, M., Denkert, C., & Darb‐Esfahani, S. (2012) · Springer eBooks · doi:10.1007/978-3-642-04564-6_21
Elmoneim, H. M. A., Mohammed, R., El-Meguid, R. A., Tawfik, H., Abd‐Elghany, M. I., Albar, H. T., Basalamah, M. A., & Toni, N. D. M. (2022) · Scientific Journal of King Faisal University Basic and Applied Sciences · doi:10.37575/b/med/220015
“The heterogeneous nature of Ov Ca histologic subtypes may affect treatment modalities and disease prognosis (Kobel et al., 2008).”
(2022) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2022.058
“The risk factors, clinical course and treatment response of EnOC are different from other ovarian cancers [16, 17].”
BackgroundShrestha, R., Llauradó, M., Dawson, A., Hoenisch, J., Volik, S. V., Lin, Y., Anderson, S. A., Kim, H. H., Haegert, A. M., Colborne, S., et al. (2023) · doi:10.1158/0008-5472.c.6513021.v1
Shrestha, R., Llauradó, M., Dawson, A., Hoenisch, J., Volik, S. V., Lin, Y., Anderson, S. A., Kim, H. H., Haegert, A. M., Colborne, S., et al. (2023) · doi:10.1158/0008-5472.c.6513021
Kauppinen, J. M., Kosma, V., Soini, Y., Sironen, R. K., Nissinen, M., Nykopp, T. K., Kärjä, V. J., Eskelinen, M. J., Kataja, V. V., & Mannermaa, A. (2023) · doi:10.1158/1055-9965.22435954
Kelemen, L. E., Goodman, M. T., McGuire, V. M., Rossing, M. A., Webb, P. M., Köbel, M., Anton‐Culver, H., Beesley, J., Berchuck, A., Brar, S., et al. (2023) · doi:10.1158/1055-9965.c.6515151
Self-citationKauppinen, J. M., Kosma, V., Soini, Y., Sironen, R. K., Nissinen, M., Nykopp, T. K., Kärjä, V. J., Eskelinen, M. J., Kataja, V. V., & Mannermaa, A. (2023) · doi:10.1158/1055-9965.c.6515185.v1
Bapat, S. A., Krishnan, A., Ghanate, A. D., Kusumbe, A. P., & Kalra, R. S. (2023) · doi:10.1158/0008-5472.c.6500256
Data from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Cheng, Z., Mirza, H., Ennis, D. P., Smith, P., Gavarró, L. M., Sokota, C., Giannone, G., Goranova, T., Bradley, T., Piskorz, A., et al. (2023) · doi:10.1158/1078-0432.c.6530898
Immunohistochemistry of Gynecologic Malignancies
Wang, Y., & Mhawech-Fauceglia, P. Y. (2023) · Springer eBooks · doi:10.1007/978-3-319-17002-2_65-2
The role of five plasma proteins in the diagnosis of ovarian tumors
Racheva, V., Ruseva, A. L., & Yordanov, A. D. (2023) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.22.04896-3
Immunohistochemistry of Gynecologic Malignancies
Wang, Y., & Mhawech-Fauceglia, P. Y. (2023) · Springer eBooks · doi:10.1007/978-3-031-14881-1_65
wang, Y., & Li, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3693253/v1
Opportunistic Salpingectomy: A New Scope of Preventing a Deadly Disease
Shermin, S., & Noor, A. (2024) · Delta Medical College Journal · doi:10.3329/dmcj.v9i1.71337
Ovarian Carcinoma - A Single Centre Case-Series Descriptive Analysis of Surgical Procedures
Subtirelu, G. D., Steriu, A., & Bratucu, E. (2024) · Chirurgia · doi:10.21614/chirurgia.3023
Differential expression of the SLC34A2 gene in different histological subtypes of ovarian carcinomas
Nurgalieva, A. K., Fetisov, T. I., Kuzin, K. A., Шакирова, Э. Ж., & Kiyamova, R. (2024) · Kazan medical journal · doi:10.17816/kmj632939
Afrose, T., Amin, R., Chowdhury, M., Elora, A. L., Jolly, R. S., & Kader, M. (2024) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20243583
Trần, T. H. Y., Nguyễn, K. D., Đỗ, T. D., Lê, V. T., Phạm, T. T. Y., & Đào, T. T. H. (2024) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v545i1.12163
Large ovarian endometrioid cystadenoma with mucinous features in a premenopausal patient
Cheon, S. H., Choi, J., Son, H. S., Lee, J. H., & Lee, W. M. (2026) · BMC Women s Health · doi:10.1186/s12905-026-04829-w
Deciphering Spatially Resolved Pathway Heterogeneity in Ovarian Cancer Post-Neoadjuvant ChemotherapyPreprint
Srivastava, A., & Vinod, P. K. U. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.08.669449
“Elevated CA125 levels are observed in HGSOC compared to healthy ovarian tissue, making it the most used molecular marker 7 .”
Prakash, S., Gundaiya, S., & Yadav, L. (2025) · doi:10.5348/100013c01sp2025cr
Zwimpfer, T. A., Fereday, S., Pandey, A., Ariyaratne, D., Jayawardana, M., Twomey, L., Laumont, C. M., Kennedy, C. J., Bolithon, A., Meagher, N. S., et al. (2025) · medRxiv · doi:10.1101/2025.09.17.25335919
Self-citationGarsed, D. W., Zwimpfer, T. A., Fereday, S., Pandey, A., Ariyaratne, D., Jayawardana, M., Twomey, L., Laumont, C. M., Kennedy, C. J., Bolithon, A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7572112/v1
“Evaluating histologically homogenous sets of ovarian tumors has been critical in deciphering the prognostic importance of proteins such as p53 2,3 and WT1 4 , and identifying genetic risk loci 5–12 .”
Self-citationDesai, M. K., Parmar, N. B., Raghani, N. R., Patel, R. B., Shah, D. D., Chorawala, M. R., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33536-5.00018-3
Context is key: how diagnostic and prognostic markers are reshaping gynecologic pathology
Köbel, M., & Karnezis, A. N. (2025) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70058
“Therefore, histotype is an effect modi fi er to prognostic biomarkers in ovarian carcinoma, and studies should analyze candidate biomarkers strati fi ed for histotype [17].”
Self-citationBürger, M., & Justus Liebig University Giessen (2014) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-14114
Identification of epigenetic events underlying ovarian carcinogenesis
Gloss, B. (2012) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/15430
Histopathological Patterns of Ovarian Masses in a University Teaching Hospital
Thakur, S., & Singh, P. (2024) · International Journal of Pharmaceutical and Clinical Research · doi:10.5281/zenodo.13363493
Němejcová, K., Šafanda, A., Bártů, M., Michálková, R., Drozenová, J., Fabián, P., Hausnerová, J., Laco, J., Matěj, R., Méhes, G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606339
Zhu, X., Shijing, Y. O. U., Du, X., Song, K., Lv, T., Zhao, H., & Yao, Q. (2023) · Figshare · doi:10.6084/m9.figshare.22602632
Ye, S., Zhou, S., Zhong, S., Shan, B., Jiang, W., Yang, W., Cai, X., & Yang, H. (2022) · Figshare · doi:10.6084/m9.figshare.19643423
Yamulla, R. J. (2020) · eCommons (Cornell University) · doi:10.7298/qs45-5555
Gonçalves, N. T. L. P. (2011) · Americanae (AECID Library)
Elschenbroich, S. (2011) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg)
Scaffold Protein-based Theranostics of HER2-overexpressing Ovarian Cancer: Imaging-guided Therapy
Xu, T. (2024) · Uppsala University Publications (Uppsala University)
Impact of tissue kallikreins on the secreted proteome of ovarian cancer cells
Shahinian, H. (2014) · FreiDok plus (Universitätsbibliothek Freiburg)
Property, Liberty and Self-Ownership in the English Revolution.
Pericleous, S. (2013) · Queen Mary Research Online (Queen Mary University of London)
CA-125 e HE4: o seu papel como biomarcadores em cancro do ovário
de Abreu, D. R. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake
Matuszewska, K., Pereira, M., Petrik, D., Lawler, J., & Petrik, J. (2021) · Cancers · doi:10.3390/cancers13174444 · Cited by 134
MiR-10a as a Modulator of Proliferation and Cell Cycle Progression in Ovarian Clear Cell Carcinoma
Collins, K. E. (2024) · IUScholarWorks (Indiana University) · doi:10.7912/2ex1-7008
PATHOMORPHOLOGICAL CHARACTERISTICS OF OVARIAN TUMORS.
Kudratova, N. (2025) · ACUMEN INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH · doi:10.5281/zenodo.18056310
Andrade, W. P. D. [. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Gupta, A. K., Kumar, D. A., Kumari, P., Monica, D., & Kumar, D. S. (2025) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v6i12.2357
Harnessing Deep Learning for Histopathological Subtyping of Ovarian Cancer: The Role of NOTCH3
Bisht, H., Beg, A., Jit, B. P., Kumar, S., & Sharma, A. (2026) · International Journal of Bioinformatics and Intelligent Computing · doi:10.61797/ijbic.v5i1.668
C-mannosyl tryptophan dynamics in a mouse model of the peritoneal dissemination of ovarian cancer
Inai, Y., Minakata, S., Tsujimoto, K., Manabe, S., Iwahashi, N., Kamijo, R., Nakadaira, Y., Nishikawa, K., Hashizume, T., Ino, K., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111359
Longuespée, R. (2012) · theses.fr (ABES) · doi:10.70675/fd1ccf55z070cz4a1ezbeb5z6edd50bb0a0d
Grube, M. P., de Souza, B. R., Neilson, A., Tinker, A., Staebler, A., Kuzma, T., Nelson, G. S., Kroon, C. D. D., Bosse, T., Kroep, J. R., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.04.008
Matheu, G., Bermejo-Pérez, M. J., Escudero-García, N., García-Durán, C., Calderó, S. G., Guerra-Alía, E. M., López-Agulló, S., Romero, I., Zambrano, G. G. Y., & Barretina-Ginesta, M. P. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04335-3
“%) and typically negative for WT1 (10%), Napsin A (3–8%), ɑ -inhibin and calretinin [12].”
Emerging biomarkers for the early detection of high-grade serous tubo-ovarian cancer
Atiq, S., Bowden, N. A., Warton, K., & Wong‐Brown, M. W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105389
Woode, M., Appah, M. A., Alhassan, E. K., Makwo, T., Asante, D.-B., & Agyirifo, D. S. (2026) · Cancer Biomarkers · doi:10.1177/18758592261468586
“Finally, given that TP53 is the most frequently mutated gene across multiple OC subtypes, 29,30 expression differences between TP53 mutant and TP53 non-mutant OC samples were evaluated to assess the molecular relevance of hub genes in the situation of TP53 dysregulation.”
Molecular Pathology of Epithelial Ovarian Cancer
Porcayo, M. A. T. (2026) · Springer eBooks · doi:10.1007/978-3-032-13454-7_37
Delahunty, R., Silva, S. S. M., Pandey, A., Garsed, D. W., Beesley, J. M., Fereday, S., Traficante, N., Craig, S., Nguyen, L. N., Hendley, J., et al. (2026) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-25-1882
“Ovarian cancer is a heterogeneous disease comprising several distinct malignancies occurring at the same anatomic site (4).”
Wang, Y., Zhao, Q., Wu, F., Ji, J., Lan, X., & He, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-10620127/v1
Farrag, M. S., Masoud, R., Hemeda, M. S., Emarah, Z. A., Elnaghi, K., Abdelwahab, K., Farrag, N. S., Ibrahiem, A. T., Ehab, Z., Elrefaie, W. E., et al. (2026) · Journal of Molecular Histology · doi:10.1007/s10735-026-10944-7
“Consequently, biomarker findings derived from mixed serous cohorts require histotype-spe-cific evaluation to exclude confounding by histologic composition (Kurman and IeM 2013; Köbel et al. 2008; Singer et al. 2003).”
卵巣明細胞がんにおける全エクソン解析を用いた変異プロファイルの同定
Koso, T. (2016) · Institutional Repositories DataBase (IRDB) · doi:10.15083/00073782
Detection of cancerous cells in the ovaries with deep icaming algorithms
Parlak, H. (2024) · Bilecik Şeyh Edebali University Institutional Repository
Liu, T., Suominen, H., Rice, G., Salomón, C., & Barnard, A. S. (2026) · Machine Learning Health · doi:10.1088/3049-477x/aeafbe
Advances in Biomarker Discovery for Early Ovarian Cancer Diagnosis
Niebora, J., Spaczyńska, J., Partyńska, A., Penciak, N., Domagała, D., Data, K., Mozdziak, P. E., Bryja, A., Chmielewski, P. P., Dąbrowski, P., et al. (2026) · Cells · doi:10.3390/cells15211940
Tutal, A. D., Purut, Y. E., DOĞAN, G. H., Sarıkaya, S., Sağlam, C., & Şancı, M. (2026) · Medicina · doi:10.3390/medicina62112145
Keleş, A. N., Yıldız, İ., Gündüz, R., Urakçı, Z., & Alabalık, U. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48111173
Na, R., Jordan, S., Anton‐Culver, H., Bandera, E. V., Cook, L. S., Cramer, D. W., DeFazio, A., Doherty, J. A., Fortner, R. T., Gayther, S. A., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00311-0
Rönnerman, E. W., Pettersson, D., Nemes, S., Dahm-Kähler, P., Kovács, A., Karlsson, P., Parris, T. Z., & Helou, K. (2023) · doi:10.3389/fonc.2022.1112152.s001
Prieske, K. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1071
Eradicating ovarian cancer stem cells in an immunosuppressive tumor microenvironment
Di, J.-B. (2013) · Radboud Repository (Radboud University)
Vallen, M. J. E. (2014) · Radboud Repository (Radboud University)
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.